- |||||||||| CoVepiT / OSE Immunotherapeutics
[VIRTUAL] CoVepiT, a Second-Generation COVID-19 Vaccine with a Multi-Target Approach Focused on CD8 T-Cell Epitopes () - Apr 4, 2021 - Abstract #PEGS2021PEGS_524;
CoVepiT has potential for an universal vaccine against coronaviruses (including all previous, currently circulating and future mutated SARS-CoV-2 variants). The technology is based on optimized CD8 T-cell epitopes:Against 11 SARS-CoV-2 proteins (S, M, N, NSPs and accessory protein)In stable (non-mutated) SARS-CoV-2 genome (analysis of > 300 000 sequences, elimination of epitopes in « hotspots » mutations region)High homology with previous SARS-CoV-1 (90-100%) and MERS (60-90%)High HLA A,B,C coverage, hence no HLA genotype restrictionImmunodominant epitopes selected based on positive response in COVID-19 convalescent versus unexposed subjects (n=120 asymptomatic, moderate and severe patients)
|
